XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Tables)
6 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of share purchase warrants outstanding
      
Number  Exercise Price  Expiry Date
 150,000   $3.17   May 6, 2024
 10,000   $12.00   April 21, 2026
 160,000         
Schedule of outstanding stock purchase options
               
                Number of Shares         Weighted Average Exercise Price
($)
      Weighted Average Grant Date Fair Value
($)
        Aggregate intrinsic value
($)
 Outstanding, September 30, 2021    11,330,903    5.74    —      140,132,451 
 Granted    2,358,000    10.13    7.07    —   
 Forfeited    (118,750)   6.86    5.23    —   
 Exercised    (400,537)   2.52    1.88    4,201,015 
 Outstanding, September 30, 2022    13,169,616    6.61         62,267,309 
 Granted    1,863,000    9.36    6.64    —   
 Exercised    (133,503)   3.29    2 59    868,537 
 Forfeited    (57,500)   11.73    9.09    —   
 Outstanding, March 31, 2023    14,841,613    6.97         43,709,206 
 Exercisable, March 31, 2023    9,937,362    4.78         43,099,822 
Schedule Of Share-based Payment Arrangement, Option, Activity
                  
Range of exercises prices  Number of Outstanding  Weighted average remaining contractual Me  Weighted average  Number of vested  Weighted average
From  To  options  (in years)  exercise price  options  exercise price
$0.92   $2.96    3,834,559    4.60   $2.29    3,834,559   $2.29 
$3.15   $4.80    2,022,500    4.82   $3.28    2,017,500   $3.28 
$5.04   $8.98    5,307,054    6.72   $6.89    3,345,720   $6.08 
$9.20   $13.01    2,118,000    8.87   $10.68    312,083   $11.94 
$13.22   $24.58    1,559,500    7.99   $18.48    427,500   $18.90 
           14,841,613    6.35   $6.97    9,937,362   $4.78 
Schedule of general and administrative expenses and research and development expenses
                    
   Three months ended March 31,  Six months end March 31,
   2023  2022  2023  2022
General and administrative  $1,256,845   $1,577,831   $2,999,370   $3,249,557 
Research and development   2,713,219    2,861,625    6,317,202    5,098,673 
Total stock-based compensation  $3,970,064   $4,439,456   $9,316,572   $8,348,230 
Schedule of weighted average assumptions for fair value of each option award
          
   2023  2022
Risk-free interest rate   3.69%   1.40%
Expected life of options (years)   5.61    4.90 
Annualized volatility   85.28%   95.88%
Dividend rate   0.00%   0.00%